Accelerate your development & understanding of viral & non-viral drug delivery vectors: from proof of concept to drug product manufacture
Cell & Gene Therapy Insights 2022; 8(9), 1195
DOI: 10.18609/cgti.2022.177
Published: 10 October 2022
FastFacts
Watch the video or view the poster to learn:
- Which analytical technologies can be used to characterize and optimize viral and lipid-based formulations
- How to analyse specific characteristics of AAV delivery vectors and lipid nanoparticles (LNPs)
- The importance of applying orthogonal analytical techniques and which techniques are complementary
- Strengths and weaknesses of various characterization techniques for the development of drug delivery vectors